Replies to post #438406 on Anavex Life Sciences Corp (AVXL)

[toemind]

Good distinction, but I'd read it as "major publication". And so we wait.
Thanks,
ToeMind

[mauismart]

So we wait for that publication. Seems like I have been waiting for it forever. They can't argue with the results if it is in a major publication.

[WilliamMunny]

I agree, boi, that the perceived quality of the journal will influence the market impact of the article. I also tend to agree with toemind that the adjective "major" should be linked with the following noun, "publication," rather than the data in the PR. The impact will be amplified or muted by the follow on reception it gets in the biotech trade press. The potentially most impactful factor, however, will be whether the story gets any ink in the mainstream media, specifically the WSJ and/or the NYT.

Anavex being a pre-revenue player in the industry notwithstanding, a drug that shows more efficacy (over a shorter period of time) than the aspiring new SOC, LEQEMBI, and does so without serious side effects and with convenient administration in pill form could attract a good bit of attention. Combine that with a significant reduction in amyloid beta levels (as well as tau and inflammation) and a significant reduction in pathological brain atrophy, as well as improved sleep and reduced blood pressure in hypertensive patients, and I am pretty sure you have a story that would interest the wider press.

[BIOChecker4]

As usual, Missling’s poor use of English leaves a simple concept open to different interpretations. By the way, we don’t need a “major” publication, whatever that might mean. What we need an influential publication, such as The New England Journal of Medicine.

Good luck and DOG bless,